Supraspinally-administered agmatine attenuates the development of oral fentanyl self-administration

Wade, Carrie L.; Schuster, Daniel J.; Domingo, Kristine M.; Kitto, Kelley F.; Fairbanks, Carolyn A.

doi:10.1016/j.ejphar.2008.04.007

Cited by 29 publications

(27 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A subset of these doses has been used in oral operant paradigms with C57BL6 (Wade et al, 2013, 2008) and three bottle choice procedures with 129-derived mice (Jimenez et al, 2017), and served as reinforcers in some cases. Under our experimental conditions, no preference was observed at any concentration tested.…”

Section: Discussionmentioning

confidence: 99%

The effect of quinine in two bottle choice procedures in C57BL6 mice: Opioid preference, somatic withdrawal, and pharmacokinetic outcomes

Grim

Park

Schmid

et al. 2018

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Previous reports assessing morphine effects in two bottle choice (TBC) paradigms often use taste adulterants such as sweeteners (e.g., saccharin) and/or bitterants (e.g., quinine) to demonstrate morphine preference with C57BL6 mice. The effect of these additional components on the morphine preference of C57BL6 remains poorly understood. Thus, we sought to elucidate the interrelationship of morphine and quinine in the TBC paradigm. As expected, when morphine was included in the opposite bottle from quinine, a preference for the morphine solution was observed. Conversely, when quinine was included in each bottle, or when fentanyl without quinine was used, no preference was observed. All opioid-drinking mice displayed withdrawal signs, and morphine was detectable in plasma and brain. When these results were compared to previous results via conversion to quinine preference scores, quinine was revealed to determine largely the measured morphine preference. Thus, quinine is effective to drive morphine consumption and engender dependence but may confound the ability to measure oral abuse liability of morphine. Together, these results suggest future TBC procedures should consider the effect of quinine upon measured preference for compounds in the opposite bottle, and that excessively high quinine concentrations appear to influence preference more so than the opposite solute when using C57BL6 mice. Alternative conditions to assess oral abuse liability may be necessary to complement and confirm results from TBC experiments utilizing morphine or other opioids.

show abstract

Section: Discussionmentioning

confidence: 99%

The effect of quinine in two bottle choice procedures in C57BL6 mice: Opioid preference, somatic withdrawal, and pharmacokinetic outcomes

Grim

Park

Schmid

et al. 2018

Drug and Alcohol Dependence

View full text Add to dashboard Cite

show abstract

“…CFA and vincristine sulfate were mixed in 0.9% NaCl. A concentration of 10 µg/ml was selected for fentanyl citrate based on our previous work that defined the optimal concentration [ 23 ]. Fentanyl is known to be a bitter solution [ 24 ].…”

Section: Methodsmentioning

confidence: 99%

Effect of Chronic Pain on Fentanyl Self-Administration in Mice

et al. 2013

Self Cite

View full text Add to dashboard Cite

The development of opioid addiction in subjects with established chronic pain is an area that is poorly understood. It is critically important to clearly understand the neurobiology associated with propensity toward conversion to addiction under conditions of chronic pain. To pose the question whether the presence of chronic pain influences motivation to self-administer opioids for reward, we applied a combination of rodent models of chronic mechanical hyperalgesia and opioid self-administration. We studied fentanyl self-administration in mice under three conditions that induce chronic mechanical hyperalgesia: inflammation, peripheral nerve injury, and repeated chemotherapeutic injections. Responding for fentanyl was compared among these conditions and their respective standard controls (naïve condition, vehicle injection or sham surgery). Acquisition of fentanyl self-administration behavior was reduced or absent in all three conditions of chronic hyperalgesia relative to control mice with normal sensory thresholds. To control for potential impairment in ability to learn the lever-pressing behavior or perform the associated motor tasks, all three groups were evaluated for acquisition of food-maintained responding. In contrast to the opioid, chronic hyperalgesia did not interfere with the reinforcing effect of food. These studies indicate that the establishment of chronic hyperalgesia is associated with reduced or ablated motivation to seek opioid reward in mice.

show abstract

“…This dual activity raises the question as to whether agmatine functions endogenously as an anti-glutamatergic neuromodulator. This proposed role for agmatine is also suggested from reports describing agmatine-mediated inhibition of opioid tolerance (Kolesnikov et al, 1996;Fairbanks and Wilcox, 1997), opioid self-administration (Morgan et al, 2002;Wade et al, 2008), inflammation-and neuropathy-induced hyperalgesia (Fair-banks et al, 2000), behavioral sequelae after spinal cord injury Gilad and Gilad, 2000; and evoked seizure (Feng et al, 2005).…”

mentioning

confidence: 90%

Immunoneutralization of Agmatine Sensitizes Mice to μ-Opioid Receptor Tolerance

Wade

Eskridge

Nguyen

et al. 2009

J Pharmacol Exp Ther

Self Cite

View full text Add to dashboard Cite

Systemically or centrally administered agmatine (decarboxylated arginine) prevents, moderates, or reverses opioid-induced tolerance and self-administration, inflammatory and neuropathic pain, and sequelae associated with ischemia and spinal cord injury in rodents. These behavioral models invoke the N-methyl-D-aspartate (NMDA) receptor/nitric-oxide synthase cascade. Agmatine (AG) antagonizes the NMDA receptor and inhibits nitric-oxide synthase in vitro and in vivo, which may explain its effect in models of neural plasticity. Agmatine has been detected biochemically and immunohistochemically in the central nervous system. Consequently, it is conceivable that agmatine operates in an anti-glutamatergic manner in vivo; the role of endogenous agmatine in the central nervous system remains minimally defined. The current study used an immunoneutralization strategy to evaluate the effect of sequestration of endogenous agmatine in acute opioid analgesic tolerance in mice. First, intrathecal pretreatment with an anti-AG IgG (but not normal IgG) reversed an established pharmacological effect of intrathecal agmatine: antagonism of NMDA-evoked behavior. This result justified the use of anti-AG IgG to sequester endogenous agmatine in vivo. Second, intrathecal pretreatment with the anti-AG IgG sensitized mice to induction of acute spinal tolerance of two -opioid receptor-selective agonists, [D-Ala 2 ,N-Me-Phe 4 ,Gly 5 -ol]-enkephalin and endomorphin-2. A lower dose of either agonist that, under normal conditions, produces moderate or no tolerance was tolerance-inducing after intrathecal pretreatment of anti-AG IgG (but not normal IgG). The effect of the anti-AG IgG lasted for at least 24 h in both NMDA-evoked behavior and the acute opioid tolerance. These results suggest that endogenous spinal agmatine may moderate glutamate-dependent neuroplasticity.

show abstract

Supraspinally-administered agmatine attenuates the development of oral fentanyl self-administration

Cited by 29 publications

References 43 publications

The effect of quinine in two bottle choice procedures in C57BL6 mice: Opioid preference, somatic withdrawal, and pharmacokinetic outcomes

The effect of quinine in two bottle choice procedures in C57BL6 mice: Opioid preference, somatic withdrawal, and pharmacokinetic outcomes

Effect of Chronic Pain on Fentanyl Self-Administration in Mice

Immunoneutralization of Agmatine Sensitizes Mice to μ-Opioid Receptor Tolerance

Contact Info

Product

Resources

About